SD0006: A Potent, Selective and Orally Available Inhibitor of p38 Kinase

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Pharmacology

• Publication date

  2009-07-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1159/000227286PMID 19590255PMCID PMC2790787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

  2012cited by this paper
• Collagen-induced arthritis in mice.

  2010cited by this paper
• TNFalpha antagonist upregulates interleukin-6 in rats with hypertensive heart failure.

  2008cited by this paper
• SB203580, a pharmacological inhibitor of p38 MAP kinase transduction pathway activates ERK and JNK MAP kinases in primary cultures of human hepatocytes.

  2008cited by this paper
• Obesity, inflammation, and insulin resistance.

  2007cited by this paper
• Collagen-induced arthritis in mice.

  2007cited by this paper
• Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity.

  2006cited by this paper
• Inhibition of p38 Mitogen-Activated Protein Kinase Prevents Inflammatory Bone Destruction

  2006cited by this paper
• Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Regulates Tumor Necrosis Factor mRNA Stability and Translation Mainly by Altering Tristetraprolin Expression, Stability, and Binding to Adenine/Uridine-Rich Element

  2006cited by this paper
• The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation.

  2006cited by this paper
• The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.

  2005cited by this paper
• Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways

  2005cited by this paper
• Why does tumor necrosis factor targeted therapy reactivate tuberculosis?

  2005cited by this paper
• Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies

  2005cited by this paper
• Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.

  2004cited by this paper
• Biologics in inflammatory bowel disease: how much progress have we made?

  2004cited by this paper
• The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation.

  2004cited by this paper
• COPD: is there light at the end of the tunnel?

  2004cited by this paper
• Infliximab monotherapy in psoriasis: A case of rapid clinical and histological response

  2004cited by this paper
• Strong inhibition of TNF-α production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor

  2004cited by this paper
• p38 Mitogen-activated protein kinase mediates synergistic induction of inducible nitric-oxide synthase by lipopolysaccharide and interferon-gamma through signal transducer and activator of transcription 1 Ser727 phosphorylation in murine aortic endothelial cells.

  2004cited by this paper
• The p38 MAP kinase pathway as a therapeutic target in inflammatory disease.

  2004cited by this paper
• Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts

  2004cited by this paper
• Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

  2004cited by this paper
• Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy.

  2003cited by this paper
• Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.

  2003cited by this paper
• The biology of TNF blockade.

  2003cited by this paper
• Infectious complications of biologic treatments of rheumatoid arthritis

  2003cited by this paper
• Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports.

  2003cited by this paper
• Post‐transcriptional regulation of gene expression by mitogen‐activated protein kinase p38

  2003cited by this paper
• Feedback control of the protein kinase TAK1 by SAPK2a/p38α

  2003cited by this paper
• p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

  2003cited by this paper
• Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.

  2002cited by this paper
• Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia1

  2002cited by this paper
• Pyridinylimidazole based p38 MAP kinase inhibitors.

  2002cited by this paper
• Immunotherapy for rheumatoid arthritis.

  2001cited by this paper
• VX-745. Vertex Pharmaceuticals.

  2001cited by this paper
• Suppression of the clinical and cytokine response to endotoxin by RWJ‐67657, a p38 mitogen‐activated protein‐kinase inhibitor, in healthy human volunteers

  2001cited by this paper
• The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.

  2001cited by this paper
• VX-745. Vertex Pharmaceuticals.

  2001cited by this paper
• TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand.

  2000cited by this paper
• Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6.

  2000cited by this paper
• SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

  2000cited by this paper
• Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

  2000cited by this paper
• p38 Mitogen-activated Protein Kinase Regulates Cyclooxygenase-2 mRNA Stability and Transcription in Lipopolysaccharide-treated Human Monocytes*

  1999cited by this paper
• Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

  1999cited by this paper
• Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages.

  1999cited by this paper
• Differential Expression and Activation of p38 Mitogen-Activated Protein Kinase α, β, γ, and δ in Inflammatory Cell Lineages

  1999cited by this paper
• Regulation of Interleukin-1β-induced Interleukin-6 Gene Expression in Human Fibroblast-like Synoviocytes by p38 Mitogen-activated Protein Kinase*

  1998cited by this paper
• Potent inhibitors of the MAP kinase p38.

  1998cited by this paper
• SB202190, a selective inhibitor of p38 mitogen‐activated protein kinase, is a powerful regulator of LPS‐induced mRNAs in monocytes

  1998cited by this paper
• The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding.

  1998cited by this paper
• Pyrroles and other heterocycles as inhibitors of p38 kinase.

  1998cited by this paper
• Taming TNF: strategies to restrain this proinflammatory cytokine.

  1997cited by this paper
• Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• [20] Processing of X-ray diffraction data collected in oscillation mode.

  1997cited by this paper
• Role of the Glycine Triad in the ATP-binding Site of cAMP-dependent Protein Kinase*

  1997influential reference
• Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution

  1994cited by this paper
• A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

  1994cited by this paper
• X-PLOR Version 3.1: A System for X-ray Crystallography and NMR

  1992cited by this paper
• Pro- and anti-inflammatory roles of interleukin-1 in recurrence of bacterial cell wall-induced arthritis in rats

  1991cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper
• Diet therapy for rheumatoid arthritis.

  1983cited by this paper

• Genetic analysis of diagnostic and therapeutic potential for ferroptosis in postoperative sepsis.

  2025cites this paper
• The journey of p38 MAP kinase inhibitors: From bench to bedside in treating inflammatory diseases.

  2024cites this paper
• Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis

  2023cites this paper
• p38MAPKa stromal reprogramming sensitizes metastatic breast cancer to immunotherapy.

  2023cites this paper
• p38 mitogen‐activated protein kinase: Functions and targeted therapy in diseases

  2023cites this paper
• Inhibitors and Activators of the p38 Mitogen- Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and Inflammation.

  2022cites this paper
• Design, synthesis, molecular docking and biological evaluation of novel 1,5-diarylpyrazole-N,O-dimethyl hydroxamate derivatives as antiproliferative agents.

  2021cites this paper
• Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.

  2020cites this paper
• p38 mitogen-activated protein kinase and pain.

  2020cites this paper
• Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis

  2019cites this paper
• AZD7624, an Inhaled p38 Inhibitor, Demonstrates Local Lung Inhibition of LPS-Induced TNFα with Minimal Systemic Exposure

  2018cites this paper
• Selective inhibition of the p38α MAPK–MK2 axis inhibits inflammatory cues including inflammasome priming signals

  2018influential citation
• Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.

  2018cites this paper
• an inhaled p38 inhibitor, demonstrate local lung inhibition of LPS-induced TNFα with minimal systemic exposure

  2018cites this paper
• Medicinal Chemistry Case History: Structure-Based Drug Design of Oral and Inhaled p38 MAP Kinase Inhibitors as Clinical Candidates

  2017cites this paper
• p38 MAPK inhibits nonsense-mediated RNA decay in response to persistent DNA damage in noncycling cells

  2017cites this paper
• Suppression of cytokine production by glucocorticoids is mediated by MKP-1 in human lung epithelial cells

  2017cites this paper
• Anti-Inflammatory Effects of β2-Receptor Agonists Salbutamol and Terbutaline Are Mediated by MKP-1

  2016cites this paper
• Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases

  2016cites this paper
• articleOptical tomographic imaging discriminates between disease-modifying anti-rheumatic drug ( DMARD ) and non-DMARD efficacy in collagen antibody-induced arthritis

  2015cites this paper
• Attenuation of TNF-α secretion by L-proline-based cyclic dipeptides produced by culture broth of Pseudomonas aeruginosa.

  2015cites this paper
• Mitogen-activated Protein Kinase Phosphatases in Inflammation and as Anti-inflammatory Drug Targets

  2014cites this paper
• p38MAPK plays a crucial role in stromal-mediated tumorigenesis.

  2014influential citation
• Regulation and Inhibition of Pro-Tumorigenic Microenvironments

  2014cites this paper
• The expression of interleukin-12 is increased by MAP kinase phosphatase-1 through a mechanism related to interferon regulatory factor 1.

  2012cites this paper
• Regulation of tristetraprolin expression by mitogen‐activated protein kinase phosphatase‐1

  2012cites this paper
• Medicinal Chemistry Approaches for the Inhibition of the p38 MAPK Pathway

  2011cites this paper
• Attenuation of the acute inflammatory response by dual specificity phosphatase 1 by inhibition of p38 MAP kinase.

  2011influential citation
• Dual Specificity Phosphatase 1 Regulates Human Inducible Nitric Oxide Synthase Expression by p38 MAP Kinase

  2011cites this paper
• Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase.

  2010cites this paper
• A Benzothiophene Inhibitor of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 Inhibits Tumor Necrosis Factor α Production and Has Oral Anti-Inflammatory Efficacy in Acute and Chronic Models of Inflammation

  2010influential citation
• Effects of p38 MAPK inhibition on early stages of diabetic retinopathy and sensory nerve function.

  2010cites this paper
• Critical role for apoptosis signal-regulating kinase 1 in the development of inflammatory K/BxN serum-induced arthritis.

  2010cites this paper
• Macrophage-colony stimulating factor and interleukin-34 induce chemokines in human whole blood.

  2010cites this paper
• Inhibition of p38 MAPK enhances ABT‐737‐induced cell death in melanoma cell lines: novel regulation of PUMA

  2010cites this paper
• Characterization of the response of melanoma cell lines to inhibition of anti-apoptotic Bcl-2 proteins

  2010cites this paper
• Anti-Inflammatory Properties of a Novel N-Phenyl Pyridinone Inhibitor of p38 Mitogen-Activated Protein Kinase: Preclinical-to-Clinical Translation

  2009influential citation
• Open Access Research Article

  year unknowncites this paper